RNF139 Antibody - N-Terminal Region Rabbit Polyclonal Antibody Catalog # AI12216

10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609

RNF139 antibody - N-terminal region Rabbit Polyclonal Antibody Catalog # AI12216

Specification

RNF139 antibody - N-terminal region - Product Information

Application WB Primary Accession Q8WU17 Other Accession NM_007218, NP_009149 Reactivity Human, Mouse, Rat, Rabbit, Pig, Horse, Bovine, Guinea Pig, Dog Predicted Rat, Rabbit, Pig, Horse, Bovine, WB Suggested Anti-RNF139 Antibody Guinea Pig, Dog Titration: 0.2-1 μg/ml Host Rabbit ELISA Titer: 1:312500 Clonality Polyclonal Calculated MW 76kDa KDa Positive Control: MCF7 cell lysate RNF139 is supported by BioGPS gene expression data to be expressed in MCF7 RNF139 antibody - N-terminal region - Additional Information

Gene ID 11236

Alias Symbol HRCA1, MGC31961, RCA1, TRC8 Other Names E3 ubiquitin-protein ligase RNF139, 6.3.2.-, RING finger protein 139, Translocation in renal carcinoma on chromosome 8 protein, RNF139 (HGNC:17023)

Format Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage Add 50 ul of distilled water. Final anti-RNF139 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

Page 1/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609

RNF139 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

RNF139 antibody - N-terminal region - Protein Information

Name RNF139 (HGNC:17023)

Function E3-ubiquitin ligase; acts as a negative regulator of cell proliferation through mechanisms involving G2/M arrest and cell death (PubMed:10500182, PubMed:12032852, PubMed:17016439). Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER) (PubMed:19720873). Affects SREBP processing by hindering the SREBP-SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression (PubMed:19706601, PubMed:20068067). Involved in the sterol-accelerated degradation of HMGCR (PubMed:22143767, PubMed:23223569). This is achieved through binding of RNF139 to INSIG1 and/or INSIG2 at the ER membrane (PubMed:22143767). In addition, interaction of RNF139 with AUP1 facilitates interaction of RNF139 with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase AMFR, leading to ubiquitination of HMGCR (PubMed:23223569). The

Page 2/3 10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609

ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction (PubMed:22143767, PubMed:23223569). Required for INSIG1 ubiquitination (PubMed:20068067). May be required for EIF3 complex ubiquitination (PubMed:20068067).

Cellular Location Endoplasmic reticulum membrane; Multi-pass membrane protein

Tissue Location Highly expressed in testis, placenta and adrenal gland. Moderate expression in heart, brain, liver, skeletal muscle and pancreas, and low expression in lung and kidney

RNF139 antibody - N-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Western Blot • Blocking Peptides • Dot Blot • Immunohistochemistry • Immunofluorescence • Immunoprecipitation • Flow Cytomety • Cell Culture

Page 3/3